Skip to main content

Hims & Hers Health, Inc. (HIMS) Stock

Hims & Hers Health, Inc. Stock Details, Movements and Public Alerts

Hims & Hers Health (HIMS): The Telehealth Platform Betting $725 Million on Weight Loss While Fighting the FDA

Andrew Dudum founded Hims & Hers in 2017 to make healthcare accessible through a direct-to-consumer telehealth model. Eight years later, the company projects $2.35 billion in 2025 revenue, with weight loss treatments accounting for roughly a third of the total. The platform connects patients with licensed providers who prescribe personalized treatments, including compounded GLP-1 medications that cost a fraction of branded alternatives like Wegovy and Ozempic. That price advantage attracted over 100,000 GLP-1 subscribers by late 2024, with only 25% discontinuing treatment at six months compared to industry averages above 50%. But the FDA has pushed back hard, warning about misleading marketing claims and restricting compounded GLP-1 ingredients in early 2026, creating the central tension in the HIMS investment case.

52-Week Range

$70.43 - $13.74

-65.01% from high · +79.33% from low

Avg Daily Volume

48,582,194

20-day average

100-day avg: 27,578,002

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

48.78

Above market average

Forward P/E

16.59

Earnings expected to grow

Price to Book

10.45

EV/EBITDA

35.38

EPS (TTM)

$0.51

Price to Sales

2.42

Beta

2.61

More volatile than market

Q:How is HIMS valued relative to its earnings and growth?
Hims & Hers Health, Inc. trades at a P/E ratio of 48.78, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 16.59 is lower than the current P/E, indicating analysts expect earnings to grow over the next year.
Q:What is HIMS's risk profile compared to the market?
With a beta of 2.61, Hims & Hers Health, Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 26% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 10.45 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

5.47%

Operating Margin

2.72%

EBITDA

$175.66M

Return on Equity

25.23%

Return on Assets

5.29%

Revenue Growth (YoY)

28.40%

Earnings Growth (YoY)

-17.40%

Q:How profitable and efficient is HIMS's business model?
Hims & Hers Health, Inc. achieves a profit margin of 5.47%, meaning it retains $5.47 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 2.72% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 25.23% and ROA at 5.29%, the company generates strong returns on invested capital.
Q:What are HIMS's recent growth trends?
Hims & Hers Health, Inc.'s revenue grew by 28.40% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings decreased by 17.40% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against Drug Manufacturers - Specialty & Generic industry averages for proper context.

Company Size & Market

Market Cap

$5.7B

Revenue (TTM)

$2.35B

Revenue/Share (TTM)

$10.44

Shares Outstanding

219.56M

Book Value/Share

$2.38

Asset Type

EQUITY

Q:What is HIMS's market capitalization and position?
Hims & Hers Health, Inc. has a market capitalization of $5.7B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 219.56M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Drug Manufacturers - Specialty & Generic industry, it competes with other firms in this sector.
Q:How does HIMS's price compare to its book value?
Hims & Hers Health, Inc.'s book value per share is $2.38, while the current stock price is $24.64, resulting in a price-to-book (P/B) ratio of 10.35. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$23.12

6.19% downside potential

Analyst Recommendations

Strong Buy

0

Buy

3

Hold

8

Sell

1

Strong Sell

2

Q:How reliable are analyst predictions for HIMS?
14 analysts cover HIMS with 21% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $23.12 implies -6.2% downside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on HIMS?
Current analyst recommendations:03 Buy, 8 Hold, 1 Sell, 2 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 17, 2026, 02:03 AM

Technical Indicators

RSI (14-day)

62.33

Neutral

50-Day Moving Average

$24.04

2.50% above MA-50

200-Day Moving Average

$42.02

-41.36% below MA-200

MACD Line

0.41

MACD Signal

-1.15

MACD Histogram

1.56

Bullish

Q:What does HIMS's RSI value tell investors?
The RSI (Relative Strength Index) for HIMS is currently 62.33, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret HIMS's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.41 above the signal line at -1.15, with histogram at 1.56. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($24.04) is below the 200-day MA ($42.02), forming a death cross pattern that often warns of extended weakness. Price is currently between the MAs, suggesting transition.

Indicators last updated: Mar 17, 2026, 01:03 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
8%
Created
Mar 16, 2026, 04:37 PM
Alert Condition
Price decreases by
Threshold
8%
Created
Mar 16, 2026, 04:37 PM
Alert Condition
Forward P/E falls below
Threshold
14.67 x
Created
Mar 13, 2026, 01:07 AM
Alert Condition
Forward P/E falls below
Threshold
9 x
Created
Mar 4, 2026, 06:19 PM

Hims & Hers Health (HIMS) Stock Analysis 2025: Complete Investment Guide

From Hair Loss Startup to Telehealth Platform

Hims launched in 2017 selling finasteride and minoxidil for hair loss through an online platform that connected customers with licensed prescribers. The model removed the friction of in-person doctor visits for conditions many men found embarrassing to discuss. CEO Andrew Dudum, a Palestinian-American entrepreneur, expanded the concept to sexual health (sildenafil, tadalafil), then added Hers for women's health. The company went public via SPAC in January 2021 at a $1.6 billion valuation.

The business has since expanded well beyond its original categories. Hims & Hers now covers dermatology (custom skin creams), mental health (therapy sessions and prescriptions), primary care, and weight management. Each category follows the same pattern: identify conditions where patients delay or avoid treatment due to cost, stigma, or inconvenience, then offer accessible telehealth consultations with personalized treatment plans shipped directly to the customer.

The Weight Loss Bet and GLP-1 Economics

Weight loss transformed the HIMS growth trajectory. The company began offering compounded semaglutide (the active ingredient in Wegovy and Ozempic) at prices far below branded versions, typically $199 to $299 per month versus $1,000+ for name-brand GLP-1 drugs. By late 2024, over 100,000 customers had enrolled in GLP-1 programs, generating roughly $240 million in annualized revenue.

Retention proved stronger than industry norms. Only 25% of HIMS GLP-1 customers discontinued treatment within six months, compared to studies showing most patients abandon branded GLP-1 therapy in that same window. The company credits its personalized dosing, ongoing provider engagement, and lower cost for reducing dropout rates. Hims & Hers projected its weight loss business would hit $725 million in 2025 revenue.

Financial Performance

  • •Q3 2025 Revenue: $599 million, up 49% year-over-year
  • •Full-Year 2025 Guidance: Approximately $2.35 billion in revenue
  • •Weight Loss Revenue: Projected $725 million for 2025, roughly 31% of total revenue
  • •GLP-1 Subscribers: 100,000+ by late 2024 with 75% six-month retention
  • •Growth Trajectory: Revenue grew 73% in Q2 2025 before moderating; full-year growth approximately 50-60%
  • •Business Model: Subscription-based with recurring revenue from ongoing treatment plans across all categories

Growth Catalysts

  • •Weight Loss Market Expansion: GLP-1 medications are projected to become a $100+ billion global market; even a small share at competitive prices represents significant revenue
  • •Cross-Selling Across Categories: Customers who enter through weight loss can be offered dermatology, mental health, and sexual health products; each additional subscription increases lifetime value
  • •Vertical Integration Benefits: Owned compounding pharmacies and fulfillment give HIMS cost control and speed advantages versus third-party pharmacy models
  • •Personalized Medicine Trend: Custom-formulated treatments create differentiation that commodity telehealth providers cannot easily replicate
  • •International Expansion: Current operations are US-focused; the UK and other English-speaking markets represent addressable opportunities

Risks and Challenges

  • •FDA Regulatory Action: The FDA restricted compounded GLP-1 ingredients in February 2026, forced removal of an oral GLP-1 product, and issued warning letters about misleading marketing. Further restrictions could eliminate the compounded weight loss business entirely
  • •Novo Nordisk Partnership Collapse: A branded partnership with Novo Nordisk lasted only three months before termination, removing a key avenue for legitimate GLP-1 distribution
  • •Compounding Legal Uncertainty: The legal basis for compounding drugs that are no longer in shortage faces ongoing court challenges; adverse rulings could shut down the GLP-1 supply
  • •Revenue Concentration Risk: Weight loss growing to 31% of revenue means regulatory action against that single category could materially impact the entire business
  • •CEO Stock Sales: Andrew Dudum has been selling HIMS shares, which some investors interpret as a bearish signal from the person with the most inside knowledge

Competitive Landscape

In telehealth, Hims & Hers competes with Teladoc Health, Ro, and GoodRx for patient attention and prescription volume. Teladoc is larger by revenue but generates most income from employer-sponsored plans rather than direct-to-consumer subscriptions. Ro operates a similar DTC model but with narrower product range. GoodRx focuses on prescription discounts rather than prescribing.

In weight loss specifically, the competition includes Amazon Pharmacy (which began offering GLP-1 prescriptions), Mark Cuban's Cost Plus Drugs, and numerous compounding pharmacies. Branded GLP-1 manufacturers Novo Nordisk and Eli Lilly represent both competitors and potential partners. HIMS differentiates on the full-stack experience: consultation, prescription, compounding, and delivery under one brand.

Who Is This Stock Suitable For?

Perfect For

  • ✓Growth investors willing to accept regulatory risk for 40-50% revenue growth
  • ✓Those who believe direct-to-consumer healthcare will capture share from traditional providers
  • ✓Investors with conviction that GLP-1 weight loss demand will overcome regulatory hurdles
  • ✓Traders comfortable with event-driven volatility around FDA decisions and earnings

Less Suitable For

  • ✗Risk-averse investors (FDA actions can cause 20-30% single-day drops)
  • ✗Income investors (no dividend, all earnings reinvested)
  • ✗Those who view compounded GLP-1 sales as legally unsustainable
  • ✗Value investors uncomfortable with high growth multiples on uncertain revenue streams

Investment Thesis

HIMS presents a binary risk profile centered on one question: can the company sustain its weight loss business through regulatory challenges? If yes, the platform benefits from a massive addressable market, strong retention metrics, and vertical integration that drives margins higher as the subscriber base grows. The non-weight-loss business in hair, skin, sexual health, and mental health already provides a substantial revenue base approaching $1.6 billion annually.

If FDA restrictions effectively kill compounded GLP-1 products, HIMS loses its fastest-growing revenue segment and must pivot the weight loss business to branded partnerships or alternative formulations. The stock would reprice to reflect a slower-growth telehealth company rather than a high-growth disruptor. CEO Dudum's track record suggests operational adaptability, but the regulatory risk is real and ongoing. Position sizing should reflect the binary nature of the GLP-1 outcome.

Conclusion

HIMS is a high-conviction trade on the future of accessible healthcare and GLP-1 weight management. The platform's breadth provides downside protection, but the stock's valuation depends heavily on weight loss revenue that faces active regulatory headwinds. Appropriate as a growth allocation for investors who understand the binary risk.
Bull Case
$65 (55% upside) - GLP-1 business survives regulatory challenges, weight loss hits $1B+ revenue, cross-selling accelerates
Base Case
$42 (flat) - Weight loss business partially impacted by FDA but adapts; core categories grow steadily at 20-25%
Bear Case
$18 (57% downside) - FDA effectively bans compounded GLP-1s, weight loss revenue collapses, market reprices to core telehealth value

Stay Ahead of the Market with Hims & Hers Health, Inc. Alerts

Set up price alerts for Hims & Hers Health, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.